These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 19528447)

  • 1. Tissue transglutaminase promotes or suppresses tumors depending on cell context.
    Chhabra A; Verma A; Mehta K
    Anticancer Res; 2009 Jun; 29(6):1909-19. PubMed ID: 19528447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transglutaminase 2: a multi-tasking protein in the complex circuitry of inflammation and cancer.
    Mehta K; Kumar A; Kim HI
    Biochem Pharmacol; 2010 Dec; 80(12):1921-9. PubMed ID: 20599779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue transglutaminase-mediated chemoresistance in cancer cells.
    Verma A; Mehta K
    Drug Resist Updat; 2007; 10(4-5):144-51. PubMed ID: 17662645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implications of increased tissue transglutaminase (TG2) expression in drug-resistant breast cancer (MCF-7) cells.
    Herman JF; Mangala LS; Mehta K
    Oncogene; 2006 May; 25(21):3049-58. PubMed ID: 16449978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transglutaminase-2: evolution from pedestrian protein to a promising therapeutic target.
    Agnihotri N; Mehta K
    Amino Acids; 2017 Mar; 49(3):425-439. PubMed ID: 27562794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue transglutaminase expression promotes cell attachment, invasion and survival in breast cancer cells.
    Mangala LS; Fok JY; Zorrilla-Calancha IR; Verma A; Mehta K
    Oncogene; 2007 Apr; 26(17):2459-70. PubMed ID: 17043648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer.
    Mehta K; Fok J; Miller FR; Koul D; Sahin AA
    Clin Cancer Res; 2004 Dec; 10(23):8068-76. PubMed ID: 15585642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Up-regulation of fibronectin and tissue transglutaminase promotes cell invasion involving increased association with integrin and MMP expression in A431 cells.
    Chen SH; Lin CY; Lee LT; Chang GD; Lee PP; Hung CC; Kao WT; Tsai PH; Schally AV; Hwang JJ; Lee MT
    Anticancer Res; 2010 Oct; 30(10):4177-86. PubMed ID: 21036738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transglutaminase 2 suppresses apoptosis by modulating caspase 3 and NF-kappaB activity in hypoxic tumor cells.
    Jang GY; Jeon JH; Cho SY; Shin DM; Kim CW; Jeong EM; Bae HC; Kim TW; Lee SH; Choi Y; Lee DS; Park SC; Kim IG
    Oncogene; 2010 Jan; 29(3):356-67. PubMed ID: 19838207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in understanding the roles of transglutaminase 2 in alcoholic steatohepatitis.
    Tatsukawa H; Kojima S
    Cell Biol Int; 2010 Feb; 34(3):325-34. PubMed ID: 20192918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue transglutaminase, inflammation, and cancer: how intimate is the relationship?
    Kumar S; Mehta K
    Amino Acids; 2013 Jan; 44(1):81-8. PubMed ID: 22083892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: delineation of a novel pathway.
    Mann AP; Verma A; Sethi G; Manavathi B; Wang H; Fok JY; Kunnumakkara AB; Kumar R; Aggarwal BB; Mehta K
    Cancer Res; 2006 Sep; 66(17):8788-95. PubMed ID: 16951195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implications of tissue transglutaminase expression in malignant melanoma.
    Fok JY; Ekmekcioglu S; Mehta K
    Mol Cancer Ther; 2006 Jun; 5(6):1493-503. PubMed ID: 16818508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of Transglutaminase 2 activity increases cisplatin cytotoxicity in a model of human hepatocarcinoma chemotherapy.
    Meshram DD; Pike CVS; Coussons PJ
    Eur J Pharmacol; 2017 Nov; 815():332-342. PubMed ID: 28943101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PKC delta and tissue transglutaminase are novel inhibitors of autophagy in pancreatic cancer cells.
    Ozpolat B; Akar U; Mehta K; Lopez-Berestein G
    Autophagy; 2007; 3(5):480-3. PubMed ID: 17507797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue transglutaminase: a new target to reverse cancer drug resistance.
    Budillon A; Carbone C; Di Gennaro E
    Amino Acids; 2013 Jan; 44(1):63-72. PubMed ID: 22130737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in the development of tissue transglutaminase (TG2) inhibitors.
    Badarau E; Collighan RJ; Griffin M
    Amino Acids; 2013 Jan; 44(1):119-27. PubMed ID: 22160259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TG2 protects neuroblastoma cells against DNA-damage-induced stress, suppresses p53 activation.
    Tucholski J
    Amino Acids; 2010 Jul; 39(2):523-32. PubMed ID: 20112034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue transglutaminase: from biological glue to cell survival cues.
    Mehta K; Fok JY; Mangala LS
    Front Biosci; 2006 Jan; 11():173-85. PubMed ID: 16146723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring of transglutaminase 2 under different oxidative stress conditions.
    Caccamo D; Currò M; Ferlazzo N; Condello S; Ientile R
    Amino Acids; 2012 Feb; 42(2-3):1037-43. PubMed ID: 21805137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.